nirsevimab被动免疫运动对Castellon 2023-24年的影响。最终结果

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica Pub Date : 2025-04-01 DOI:10.1016/j.eimc.2024.11.007

Eulalia Gregori-García , Juan Carlos Gascó-Laborda , Lledó Lluch-Bacas , Oscar Pérez-Olaso , Iris Gómez-Alfaro , Juan B. Bellido-Blasco

{"title":"nirsevimab被动免疫运动对Castellon 2023-24年的影响。最终结果","authors":"Eulalia Gregori-García , Juan Carlos Gascó-Laborda , Lledó Lluch-Bacas , Oscar Pérez-Olaso , Iris Gómez-Alfaro , Juan B. Bellido-Blasco","doi":"10.1016/j.eimc.2024.11.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>In the 2023-2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed.</div></div><div><h3>Methods</h3><div>Pre-post ecological study comparing 2023-24 vs 2022-23 season. The variation in incidence is described by age groups (0-5, 6-11 and 12-59months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group.</div></div><div><h3>Results</h3><div>The results were very heterogeneous depending on the age group. In children 0-5months old the RR was 0.16 (0.10-0.25); in those aged 6-11months, RR of 0.90 (0.56-1.42); and in those aged 12-59months, RR 1.36 (1.06-1.74). The greatest decrease in risk was in hospitalized children under 6months, RR 0.13 (0.07-0.22).</div></div><div><h3>Conclusion</h3><div>The results support the positive impact that this campaign had, especially on hospitalizations.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 4","pages":"Pages 215-218"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impacto de la campaña de inmunización pasiva con nirsevimab en 2023-24 en Castellón. Resultados finales\",\"authors\":\"Eulalia Gregori-García , Juan Carlos Gascó-Laborda , Lledó Lluch-Bacas , Oscar Pérez-Olaso , Iris Gómez-Alfaro , Juan B. Bellido-Blasco\",\"doi\":\"10.1016/j.eimc.2024.11.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>In the 2023-2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed.</div></div><div><h3>Methods</h3><div>Pre-post ecological study comparing 2023-24 vs 2022-23 season. The variation in incidence is described by age groups (0-5, 6-11 and 12-59months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group.</div></div><div><h3>Results</h3><div>The results were very heterogeneous depending on the age group. In children 0-5months old the RR was 0.16 (0.10-0.25); in those aged 6-11months, RR of 0.90 (0.56-1.42); and in those aged 12-59months, RR 1.36 (1.06-1.74). The greatest decrease in risk was in hospitalized children under 6months, RR 0.13 (0.07-0.22).</div></div><div><h3>Conclusion</h3><div>The results support the positive impact that this campaign had, especially on hospitalizations.</div></div>\",\"PeriodicalId\":11608,\"journal\":{\"name\":\"Enfermedades infecciosas y microbiologia clinica\",\"volume\":\"43 4\",\"pages\":\"Pages 215-218\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Enfermedades infecciosas y microbiologia clinica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0213005X24003409\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X24003409","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

在2023-2024季节，西班牙推荐使用单克隆抗体nirsevimab进行系统免疫。分析了该免疫规划对目标人群的影响。方法对2023-24季节和2022-23季节进行前后生态对比研究。发病率的差异根据年龄组（0-5个月、6-11个月和12-59个月）和住院情况来描述。计算每组的发病率并估计相对危险度（RR）。结果不同年龄组的结果差异很大。0 ~ 5月龄儿童的RR为0.16 (0.10 ~ 0.25)；6 ~ 11月龄，RR为0.90 (0.56 ~ 1.42)；12 ~ 59月龄的RR为1.36（1.06 ~ 1.74）。6个月以下住院儿童的风险降低幅度最大，RR为0.13（0.07-0.22）。结论结果支持了该运动的积极影响，特别是在住院方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impacto de la campaña de inmunización pasiva con nirsevimab en 2023-24 en Castellón. Resultados finales

Introduction

In the 2023-2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed.

Methods

Pre-post ecological study comparing 2023-24 vs 2022-23 season. The variation in incidence is described by age groups (0-5, 6-11 and 12-59 months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group.

Results

The results were very heterogeneous depending on the age group. In children 0-5 months old the RR was 0.16 (0.10-0.25); in those aged 6-11 months, RR of 0.90 (0.56-1.42); and in those aged 12-59 months, RR 1.36 (1.06-1.74). The greatest decrease in risk was in hospitalized children under 6 months, RR 0.13 (0.07-0.22).

Conclusion

The results support the positive impact that this campaign had, especially on hospitalizations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Enfermedades infecciosas y microbiologia clinica 医学-传染病学

CiteScore

2.10

自引率

8.00%

发文量

194

审稿时长

29 days

期刊介绍： Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.